Compare Sanofi SA (SNY) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Williams Companies Inc — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Williams Companies Inc trades at $73.43 (market cap $90.70B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| SNY | WMB | |
|---|---|---|
Market Cap | $104.83B | $90.70B |
Sector | Health | Energy |
52-Week High | $52.34 | $79.40 |
52-Week Low | $41.33 | $56.51 |
Enterprise Value | $121.32B | $120.08B |
Dividend Yield | 5.5% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Williams Companies (WMB) trades at $73.36, showing minimal daily movement with a slight 0.03% decline. The stock demonstrates strong profitability with 23.4% net income margins and 21.95% ROE, though valuation metrics appear elevated with a P/E of 32.53. Recent developments include a $5.34 billion Blackstone-led investment for power innovation projects and potential $5.5 billion Momentum Midstream acquisition, positioning the company for strategic growth in energy infrastructure.
WMB presents a compelling investment case with strong analyst support (79% buy ratings) and $86 consensus price target representing 17% upside. The company's fee-based midstream model provides revenue stability, while recent strategic investments enhance growth prospects. Key risks include commodity price volatility, execution challenges from major acquisitions, and elevated debt levels at 52% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
